AmberGen

AmberGen

生物技术研究

Billerica,MA 1,054 位关注者

Transforming Diagnostics & Drug Discovery

关于我们

AmberGen? is a biotechnology company and producer of Miralys? spatial biology imaging solutions. Miralys?, also known as MALDI HiPLEX-IHC, is a new breakthrough method for targeted intact protein imaging that has unique multimodal imaging capabilities. First introduced in 2022, it has gained significant traction, including 8 of the top 10 pharma companies, as well as many of the world’s premier research institutions. It is currently being used to study tissues for a wide range of diseases including cancers, Alzheimer’s and Parkinson’s diseases; and even COVID. Benefits include: - Drug/target co-localization on the same sample, same instrument - The ability to produce images that co-register small molecule lipids and metabolites as well as the intact targeted proteins. - The product’s combination of fast, targeted, protein imaging (scan time as short as 45 min and 1cm2), ultra-high plex (10 to 100+), wide viewing area (up to 25 x 75 mm), and multi-modal capability make it an ideal technology for doing initial scans to identify regions of interest for later deep-dive analysis. - Miralys? requires no dedicated instrument, and minimal investment to start using. It is used on MALDI Mass Spec Imaging instruments that your institution most likely already owns, such as the industry-leading instruments from our partner, Bruker Corporation.

网站
https://www.AmberGen.com
所属行业
生物技术研究
规模
11-50 人
总部
Billerica,MA
类型
私人持股
创立
1993
领域
mass spectrometry、MALDI、MALDI Imaging、MSI和Spatial Biology

地点

AmberGen员工

动态

相似主页

查看职位

融资

AmberGen 共 3 轮

上一轮

补助

US$200,000.00

投资者

MassVentures
Crunchbase 上查看更多信息